Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Dietary gangliosides are present in human milk and consumed in low amounts from organ meats. Clinical and animal studies indicate that dietary gangliosides attenuate signaling processes that are a hallmark of inflammatory bowel disease (IBD). Gangliosides decrease pro-inflammatory markers, improve intestinal permeability, and reduce symptoms characteristic in patients with IBD. The objective of this study was to examine mechanisms by which dietary gangliosides exert beneficial effects on intestinal health. Studies were conducted using CaCo-2 intestinal epithelial cells. Gangliosides were extracted from milk powder and incubated with differentiated CaCo-2 cells after exposure to pro-inflammatory stimuli. Gut barrier integrity was assessed by electron microscopy, epithelial barrier function was examined by measuring transepithelial electric resistance, and content of HBD-2, IL-23, NF-κB, and sPLA was assessed by ELISA. Ganglioside attenuated the decrease in integrity of tight junctions induced by pro-inflammatory stimuli and improved epithelial barrier function ( < 0.05). Ganglioside decreased the basolateral secretion of sPLA ( ≤ 0.05), lowered HBD-2 and IL-23 levels ( ≤ 0.05), and inhibited NF-κB activation ( ≤ 0.05). In summary, the present study indicates that ganglioside GD3 improves intestinal integrity by altering sPLA trafficking, and the production of pro-inflammatory mediators is mitigated by decreasing assembly of the NF-κB complex. Dietary gangliosides may have promising potential beneficial effects in IBD as decreased inflammatory signaling, improved intestinal integrity, and maintenance of epithelial barrier function have been demonstrated .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286996PMC
http://dx.doi.org/10.3389/fnut.2021.705172DOI Listing

Publication Analysis

Top Keywords

dietary gangliosides
16
epithelial barrier
12
barrier function
12
≤ 005
12
beneficial effects
8
pro-inflammatory stimuli
8
hbd-2 il-23
8
intestinal integrity
8
gangliosides
6
integrity
5

Similar Publications

Deficiency of Ugcg in LSECs alleviates high-fat diet-induced MASLD.

Hepatol Commun

September 2025

State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.

Background: Hepatic glycosphingolipid biosynthesis is implicated in insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD). While UDP-glucose ceramide glucosyltransferase (UGCG) serves as the rate-limiting enzyme in glycosphingolipid synthesis, its cell-specific roles in MASLD pathogenesis remain undefined. Our study investigates the mechanistic contribution of LSEC-expressed UGCG to high-fat diet (HFD)-induced insulin resistance and MASLD progression.

View Article and Find Full Text PDF

SLC35A2-CDG is an X-linked congenital disorder of glycosylation (CDG), characterized by defective UDP-galactose transport into the Golgi and endoplasmic reticulum and consequent insufficient galactosylation of glycans. Clinically, this translates into a range of predominantly neurological symptoms. Although the pathomechanism of this disorder is not fully understood, oral galactose supplementation has led to clinical and biochemical improvement in some patients.

View Article and Find Full Text PDF

Blood Metabolic Biomarkers of Diabetes Mellitus Type 2 in Aged Adults Determined by a UPLC-MS Metabolomic Approach.

Metabolites

June 2025

Máster en Nutrición Geriátrica, Departamento de Pediatría e Inmunología, Obstetricia y Ginecología, Nutrición y Bromatología, Psiquiatría e Historia de la Ciencia, Universidad de Valladolid, 47005 Valladolid, Spain.

Type 2 diabetes mellitus (T2DM) is a metabolic disease whose importance rises with aging, though it is also looming large in younger populations due to increasing obesity. Its effects may damage renal and heart functioning. Plasma biomarkers of T2DM have been shown through metabolomic studies under different conditions, mainly obesity, but untargeted metabolomic studies on T2DM are lacking for elderly people.

View Article and Find Full Text PDF

Background And Aims: Empagliflozin (EMPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is cardioprotective in acute myocardial infarction (AMI) including fewer hospitalizations for heart failure. However, the underlying metabolic and immunomodulatory mechanisms remain incompletely characterized. This study investigates the metabolic effects of EMPA in diabetic and non-diabetic conditions, as well as on AMI-induced immune responses.

View Article and Find Full Text PDF

Aims/hypothesis: Type 2 diabetes is a chronic metabolic disorder characterised by insulin resistance and sustained hyperglycaemia, and is a major cause of blindness, kidney failure, heart attacks and stroke. Our team has recently identified hexosaminidase A (HEXA) as an endocrine factor secreted by the liver that regulates sphingolipid metabolism in skeletal muscle. Specifically, HEXA converts GM2 to GM3 gangliosides within cell-surface lipid rafts.

View Article and Find Full Text PDF